hydralazine + valproate + nilotinib

**Hydralazine + valproate + nilotinib** is an experimental combination therapy leveraging epigenetic modulation and targeted kinase inhibition for cancer treatment, particularly in contexts like chronic myeloid leukemia (CML) resistant to prior therapies. Hydralazine acts as a DNA methyltransferase inhibitor, valproate (valproic acid) inhibits histone deacetylases (HDACs), and nilotinib is a BCR-ABL tyrosine kinase inhibitor. While hydralazine + valproate has been studied in phase I trials for advanced solid tumors showing tolerability and some stable disease, and hydralazine + valproate specifically reverses imatinib resistance in CML via epigenetic mechanisms, no published clinical data exists for the exact three-drug combination, suggesting potential synergy for overcoming resistance in hematologic and solid malignancies.